[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527249":3},{"organization":4,"armGroups":7,"interventions":109,"overallOfficials":196,"centralContacts":201,"locations":208,"responsibleParty":236,"collaborators":238,"id":241,"slug":242,"hasResults":243,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":206,"eligibilityCriteria":247,"healthyVolunteers":243,"sex":248,"minAge":249,"maxAge":250,"enrollmentInfo":251,"targetDuration":206,"studyType":254,"phases":255,"briefSummary":257,"conditions":258,"keywords":206,"overallStatus":211,"whyStopped":206,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},{"fullName":5,"class":6},"Peking Union Medical College","OTHER",[8,14,19,24,29,34,39,44,49,54,59,64,69,74,79,84,89,94,99,104],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 (HER2-positive, RC48-ADC)","EXPERIMENTAL","Disitamab vedotin 2.5 mg\u002Fkg will be administered as an intravenous infusion every 2 weeks (Q2W) as monotherapy, or in combination with physician-selected platinum-based chemotherapy (carboplatin 200-250 mg\u002Fm² IV Q2W or cisplatin 50 mg\u002Fm² IV Q2W).",[13],"Drug: Cohort 1 (HER2-positive, RC48-ADC)",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 (NTRK-fusion or NTRK-mutant)","larotrectinib 100 mg orally twice daily or entrectinib 600 mg orally once daily;",[18],"Drug: Cohort 2 (NTRK-fusion or NTRK-mutant)",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)","leuprolide 3.75 mg subcutaneously every 4 weeks, bicalutamide 50 mg orally once daily, and abiraterone 1 000 mg orally once daily.",[23],"Drug: Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort 4 (TROP2 ADC)","ESG401 16 mg\u002Fkg IV (days 1, 8, 15, q4w), sacituzumab govitecan 10 mg\u002Fkg IV (days 1 \\& 8, q3w), or sacituzumab tirumotecan 5 mg\u002Fkg IV q2w.",[28],"Drug: TROP2 ADC",{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort 5 (ACC-TKI)","apatinib 250 mg qd po or anlotinib 12 mg",[33],"Drug: TKI",{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort 6 (albumin-bound paclitaxel + platinum)","albumin-bound paclitaxel 260 mg\u002Fm² IV q3w plus physician-selected cisplatin 75 mg\u002Fm² IV q3w or carboplatin 350 mg\u002Fm² IV q3w.",[38],"Drug: Albumin-paclitaxel + platinum",{"label":40,"type":10,"description":41,"interventionNames":42},"Cohort 7 (albumin-bound paclitaxel + carboplatin + apatinib + camrelizumab)","albumin-bound paclitaxel 260 mg\u002Fm² IV q3w, carboplatin 350 mg\u002Fm² IV q3w, camrelizumab 200 mg IV q3w, and apatinib 250 mg qd po.",[43],"Drug: Albumin-paclitaxel + carboplatin + apatinib + camrelizumab",{"label":45,"type":10,"description":46,"interventionNames":47},"Cohort 8 (HER2-positive, albumin-bound paclitaxel + trastuzumab + pyrotinib)","albumin-bound paclitaxel 260 mg\u002Fm² + trastuzumab (loading 8 mg\u002Fkg → 6 mg\u002Fkg IV q3w) + pyrotinib 400 mg PO qd.",[48],"Drug: albumin-bound paclitaxel+trastuzumab+pyrotinib",{"label":50,"type":10,"description":51,"interventionNames":52},"Cohort 9 (HER2-positive, DS-8201 ± pertuzumab)","trastuzumab deruxtecan 5.4 mg\u002Fkg IV q3w ± pertuzumab (loading 840 mg → 420 mg IV q3w).",[53],"Drug: HER2,trastuzumab deruxtecan± pertuzumab",{"label":55,"type":10,"description":56,"interventionNames":57},"Cohort 10 (HER2+\u002FAR+, AR antagonist + goserelin + pertuzumab + trastuzumab)","Darolutamide 600mg po bid \u002F Enzalutamide 160mg po qd \u002F Apalutamide 240mg po qd \u002F Rivarutamide 240mg po qd + goserelin 10.8 mg SC q12w + pertuzumab\u002Ftrastuzumab loading 15 mL → 10 mL SC q3w.",[58],"Drug: AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab",{"label":60,"type":10,"description":61,"interventionNames":62},"Cohort 11 (AR-positive, AR antagonist+ goserelin ± docetaxel)","Darolutamide 600mg po bid \u002F Enzalutamide 160mg po qd \u002F Apalutamide 240mg po qd \u002F Rivarutamide 240mg po qd+ goserelin 10.8 mg SC q12w ± docetaxel 75 mg\u002Fm² IV q3w.",[63],"Drug: AR,AR antagonist +goserelin +docetaxel",{"label":65,"type":10,"description":66,"interventionNames":67},"Cohort 12 (ivonescimab)","ivonescimab 20 mg\u002Fkg + investigator-choice platinum doublet (albumin-paclitaxel 260 mg\u002Fm², liposomal paclitaxel 175 mg\u002Fm², docetaxel 75 mg\u002Fm², or vinorelbine 25 mg\u002Fm² d1,d8) plus cisplatin 75 mg\u002Fm² or carboplatin AUC 5-6 IV q3w.",[68],"Drug: ivonescimab + investigator-choice platinum doublet+",{"label":70,"type":10,"description":71,"interventionNames":72},"Cohort 13 (iparomlimab + tuvonralimab)","iparomlimab 5 mg\u002Fkg + platinum doublet (as above) ± bevacizumab 5 mg\u002Fkg IV q3w.",[73],"Drug: iparomlimab + tuvonralimab",{"label":75,"type":10,"description":76,"interventionNames":77},"Cohort 14 (cadonilimab)","cadonilimab 10 mg\u002Fkg + platinum doublet (as above) ± bevacizumab 5 mg\u002Fkg IV q3w.",[78],"Drug: cadonilimab",{"label":80,"type":10,"description":81,"interventionNames":82},"Cohort 15 (HR-positive)","CDK4\u002F6 inhibitor (abemaciclib 150 mg PO bid or palbociclib 125 mg PO qd) plus AI (letrozole 2.5 mg, anastrozole 1 mg, or exemestane 20 mg PO qd) or fulvestrant 500 mg IM q4w",[83],"Drug: CDK4\u002F6 inhibitor+AI or fulvestrant",{"label":85,"type":10,"description":86,"interventionNames":87},"Cohort 16 (PI3K-mutant)","alpelisib 300 mg PO qd plus fulvestrant 500 mg IM q4w.",[88],"Drug: alpelisib+fulvestrant",{"label":90,"type":10,"description":91,"interventionNames":92},"Cohort 17 (homologous-recombination-deficient)","PARP inhibitor (olaparib 300 mg PO bid, niraparib 300 mg PO qd, fluzoparib 150 mg PO bid, or pamiparib 60 mg PO bid).",[93],"Drug: PARP inhibitor",{"label":95,"type":10,"description":96,"interventionNames":97},"Cohort 18 (Nectin-4 ADC)","enfortumab vedotin 1.25 mg\u002Fkg IV d1,d8,d15 (max 125 mg) ± ICI (pembrolizumab 200 mg, camrelizumab 200 mg, or toripalimab 240 mg IV q3w).",[98],"Drug: enfortumab vedotin",{"label":100,"type":10,"description":101,"interventionNames":102},"Cohort 19 (HER2-positive, pyrotinib + pertuzumab + trastuzumab)","pyrotinib 400 mg PO qd + pertuzumab\u002Ftrastuzumab loading 15 mL → 10 mL SC q3w.",[103],"Drug: HER2, pyrotinib + pertuzumab\u002Ftrastuzumab",{"label":105,"type":10,"description":106,"interventionNames":107},"⑳ Cohort 20 (vebecotutamab ±lenvatinib):","verbecotutamab 2.0 mg\u002Fkg ivgtt ± lenvatinib 8mg qd q3w",[108],"Drug: vebecotutamab ±lenvatinib",[110,116,120,124,128,132,136,140,145,150,154,159,163,167,171,175,179,183,187,191],{"type":111,"name":9,"description":112,"armGroupLabels":113,"otherNames":114},"DRUG","Neoadjuvant \u002F conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.\n\nAdjuvant phase: Treatment is administered for 1 years, or until intolerable toxicity or withdrawal of consent.\n\nSalvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate.",[9],[115],"HER2,Vedolizumab",{"type":111,"name":15,"description":112,"armGroupLabels":117,"otherNames":118},[15],[119],"NTRK-inhibitor",{"type":111,"name":20,"description":112,"armGroupLabels":121,"otherNames":122},[20],[123],"AR,leuprolide + bicalutamide + abiraterone",{"type":111,"name":125,"description":112,"armGroupLabels":126,"otherNames":127},"TROP2 ADC",[25],[25],{"type":111,"name":129,"description":112,"armGroupLabels":130,"otherNames":131},"TKI",[30],[30],{"type":111,"name":133,"description":112,"armGroupLabels":134,"otherNames":135},"Albumin-paclitaxel + platinum",[35],[35],{"type":111,"name":137,"description":112,"armGroupLabels":138,"otherNames":139},"Albumin-paclitaxel + carboplatin + apatinib + camrelizumab",[40],[40],{"type":111,"name":141,"description":112,"armGroupLabels":142,"otherNames":143},"albumin-bound paclitaxel+trastuzumab+pyrotinib",[45],[144],"Cohort8 (HER2-positive, albumin-bound paclitaxel + trastuzumab + pyrotinib)",{"type":111,"name":146,"description":112,"armGroupLabels":147,"otherNames":148},"HER2,trastuzumab deruxtecan± pertuzumab",[50],[149],"Cohort9(HER2-positive, DS-8201 ± pertuzumab)",{"type":111,"name":151,"description":112,"armGroupLabels":152,"otherNames":153},"AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab",[55],[55],{"type":111,"name":155,"description":112,"armGroupLabels":156,"otherNames":157},"AR,AR antagonist +goserelin +docetaxel",[60],[158],"Cohort 11 (AR-positive, AR antagonist + goserelin ± docetaxel)",{"type":111,"name":160,"description":112,"armGroupLabels":161,"otherNames":162},"ivonescimab + investigator-choice platinum doublet+",[65],[65],{"type":111,"name":164,"description":112,"armGroupLabels":165,"otherNames":166},"iparomlimab + tuvonralimab",[70],[70],{"type":111,"name":168,"description":112,"armGroupLabels":169,"otherNames":170},"cadonilimab",[75],[75],{"type":111,"name":172,"description":112,"armGroupLabels":173,"otherNames":174},"CDK4\u002F6 inhibitor+AI or fulvestrant",[80],[80],{"type":111,"name":176,"description":112,"armGroupLabels":177,"otherNames":178},"alpelisib+fulvestrant",[85],[85],{"type":111,"name":180,"description":112,"armGroupLabels":181,"otherNames":182},"PARP inhibitor",[90],[90],{"type":111,"name":184,"description":112,"armGroupLabels":185,"otherNames":186},"enfortumab vedotin",[95],[95],{"type":111,"name":188,"description":112,"armGroupLabels":189,"otherNames":190},"HER2, pyrotinib + pertuzumab\u002Ftrastuzumab",[100],[100],{"type":111,"name":192,"description":112,"armGroupLabels":193,"otherNames":194},"vebecotutamab ±lenvatinib",[105],[195],"Cohort 20 (vebecotutamab ±lenvatinib)",[197],{"name":198,"affiliation":199,"role":200},"Jie Zhang","Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","PRINCIPAL_INVESTIGATOR",[202],{"name":203,"role":204,"phone":205,"phoneExt":206,"email":207},"fei Ma","CONTACT","13910217780",null,"drmafei@126.com",[209,227],{"facility":210,"status":211,"city":212,"state":213,"zip":214,"country":215,"countryCode":216,"cosmosGeoPoint":217,"geoPoint":222,"contacts":223},"Fei Ma","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":218,"coordinates":219},"Point",[220,221],116.39723,39.9075,{"lat":221,"lon":220},[224],{"name":225,"role":204,"phone":226,"phoneExt":206,"email":207},"Fei Ma, MD","+86-10-87787652",{"facility":228,"status":211,"city":212,"state":206,"zip":206,"country":215,"countryCode":216,"cosmosGeoPoint":229,"geoPoint":231,"contacts":232},"National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College",{"type":218,"coordinates":230},[220,221],{"lat":221,"lon":220},[233],{"name":234,"role":204,"phone":235,"phoneExt":206,"email":207},"Fei Ma, Dr.","13718455257",{"type":200,"investigatorFullName":210,"investigatorTitle":237,"investigatorAffiliation":5,"oldNameTitle":206,"oldOrganization":206},"Chief physician and deputy chief of internal medicine",[239],{"name":240,"class":6},"Peking University Hospital of Stomatology","100527249","phase-2-precision-treatment-of-recurrentmetastatic-salivary-gland-carcinoma-guided-by-molecular-typing-100527249",false,"NCT06145308","Precision Treatment of Recurrent\u002FMetastatic Salivary Gland Carcinoma Guided by Molecular Typing","Cancer Hospital, Chinese Academy of Medical Sciences\u002FNational Cancer Center of China","Inclusion Criteria:\n\n* Patients with histopathologic diagnosis of salivary gland carcinoma\n\n  * The tumor tissues were subjected to HER2\u002FNTRK\u002FAR\u002FTROP-2 immunohistochemical staining.\n\n    * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;\n\n      * Age 18 or older - no upper limit;\n\n        * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;\n\n          ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:\n\n          ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation\u002Foperation;\n\n          ⑩Ability to comply with research visit schedules and other programmatic requirements.\n\nExclusion Criteria:\n\n* Known hypersensitivity or delayed anaphylaxis to any agents in this trial;\n\n  * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;\n\n    * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;\n\n      * To study the occurrence of arterial\u002Fvenous thrombosis events within 6 months before medication;\n\n        * Major cardiovascular diseases;\n\n          * Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;\n\n            * Is suffering from an active infection that requires systemic treatment;\n\n              * History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female\u002Fmale who is pregnant or breastfeeding or who intends to give birth;","ALL","18 Years","100 Years",{"count":252,"type":253},39,"ESTIMATED","INTERVENTIONAL",[256],"PHASE2","Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.",[259,260],"Salivary Gland Carcinoma","Precision Therapy","2026-03-27",{"date":263,"type":264},"2026-04-02","ACTUAL",{"date":266,"type":264},"2023-08-15",{"date":268,"type":253},"2028-07-10",{"name":5,"class":6},2]